Title: The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA.CER) trial: study design and rationale
Authors: Harrington, Robert A ×
Van de Werf, Frans
Armstrong, Paul W
Aylward, Phil
Veltri, Enrico
Mahaffey, Kenneth W
Moliterno, David J
Strony, John
Wallentin, Lars
White, Harvey D
Diaz, Rafael
Huber, Kurt
Nicolau, Jose Carlos
Carlos Prieto, Juan
Isaza, Daniel
Widimsky, Petr
Grande, Peer
Nieminen, Markku
Montalescot, Gilles
Bode, Christoph
Wong, Lawrence
Ofner, Peter
Lewis, Basil S
Ambrosio, Giuseppe
Valgimigli, Marco
Ogawa, Hisao
Yamaguchi, Jun-ichi
Jukema, J. Wouter
Cornel, Jan H
Nordrehaug, Jan Erik
Ruzyllo, Witold
Providencia, Luis
Tan, Huay-Cheem
Dalby, Anthony
Seung-Jung, Park
Betriu, Amadeo
Cequier, Angel
Held, Claes
Pfisterer, Mathias
Ming-Fong, Chen
Timurkaynak, Timur
Storey, Robert F
Chen, Edmond
Hudson, Michael P
Lincoff, A. Michael
Morrow, David A
Tricoci, Pierluigi
Whellan, David #
Issue Date: Sep-2009
Publisher: Mosby-elsevier
Series Title: American heart journal vol:158 issue:3 pages:327-U5
Abstract: Background The protease-activated receptor 1 (PAR-1), the main platelet receptor for thrombin, represents a novel target for treatment of arterial thrombosis, and SCH 530348 is an orally active, selective, competitive PAR-1 antagonist. We designed TRA.CER to evaluate the efficacy and safety of SCH 530348 compared with placebo in addition to standard of care in patients with non-ST-segment elevation (NSTE) acute coronary syndromes (ACS) and high-risk features.
ISSN: 0002-8703
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Cardiology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science